Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease

Neurobiology of Aging

Volumn 28, Issue 6, 2007, Pages 824-830

  Zhao, Zhong ^a,b   Xiang, Zhongmin ^a   Haroutunian, Vahram ^a   Buxbaum, Joseph D ^a   Stetka, Breton ^a   Pasinetti, Giulio Maria ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amyloid; CDR; IDE; MCI

Indexed keywords

AMYLOID BETA PROTEIN; CYTOPLASM PROTEIN; INSULINASE; MEMBRANE ENZYME;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; HIGH RISK POPULATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INSULIN DEGRADATION; MALE; OCCIPITAL CORTEX; PRIORITY JOURNAL; TISSUE SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; CELL MEMBRANE; COGNITION DISORDERS; CYTOSOL; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMANS; INSULIN; INSULYSIN; IODINE ISOTOPES; MALE; POSTMORTEM CHANGES;

EID: 34247100646     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.05.001     Document Type: Article

References (18)

1. Caccamo A., Oddo S., Sugarman M.C., Akbari Y., and Laferla F.M. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26 (2005) 645-654
2. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8 (2005) 79-84
3. Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162 (2003) 313-319
4. Craft S., and Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3 (2004) 169-178
5. Dickerson B.C., Salat D.H., Greve D.N., Chua E.F., Rand-Giovannetti E., Rentz D.M., et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65 (2005) 404-411
6. Duckworth W.C. Insulin degradation: mechanisms, products, and significance. Endocr Rev 9 (1988) 319-345
7. Farris W., Mansourian S., Leissring M.A., Eckman E.A., Bertram L., Eckman C.B., et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 164 (2004) 1425-1434
8. Kurochkin I.V., and Goto S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345 (1994) 33-37
9. Lehman E.J., Kulnane L.S., and Lamb B.T. Alterations in beta-amyloid production and deposition in brain regions of two transgenic models. Neurobiol Aging 24 (2003) 645-653
10. Morris J.C. Mild cognitive impairment and preclinical Alzheimer's disease. Geriatrics Suppl (2005) 9-14
11. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58 (2001) 397-405
12. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 (2000) 1571-1577
13. Petersen R.C., and Morris J.C. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62 (2005) 1160-1163
14. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273 (1998) 32730-32738
15. Selkoe D.J. Deciphering Alzheimer's disease: the amyloid precursor protein yields new clues. Science 248 (1990) 1058-1060
16. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 20 (2000) 1657-1665
17. Walsh D.M., Klyubin I., Shankar G.M., Townsend M., Fadeeva J.V., Betts V., et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33 (2005) 1087-1090
18. Zhao Z., Ho L., Wang J., Qin W., Festa E.D., Mobbs C., et al. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance-associated promotion of Alzheimer's disease beta-amyloid neuropathology. FASEB J 19 (2005) 2081-2082